Does Number 7 Cream Really Work?
People all over Britain recently went into a frenzy to purchase a new anti-aging product called Number 7 Restore and Renew.
The cream sold out across the country in March after being featured on a television show and having a low price tag helped as well.
Independent scientists agreed with the makers about what the product can do. "We were astounded to be honest," said Dr. Rachel Watson, a Manchester University researcher. "When we started this research, we were absolutely convinced that nothing could touch the action that we see with medicine that we can use to repair photo-aged skin. So, we were very surprised to see any positive results at all."
Permanent Wrinkle Filler - Artefill
Artefill is a permanent dermal filler injected under the skin for deep facial creases. Produced by Artes Medical, its an improved version of Artecoll, which has been used in Europe and Canada on more than 400,000 patients during the past 10 years. ArteFill was FDA approved in October 2006 for the treatment of smile lines (nasolabial folds). Other off-label uses include lip augmentation, acne scars, creases and folds around the forehead, nose, mouth and eyes.
The makeup of ArteFill is a gel filler consisting of millions of synthetic microspheres (polymethylmethacrylate or PMMA) suspended in purified bovine (cow) collagen. ArteFill also contains a local anesthetic called lidocaine which reduces discomfort during injection.
Micro Fractional CO2 Laser Skin Rejuvenation
Micro Fractional CO2 Laser Skin Rejuvenation is the treatment of choice for acne scars or signs of aging like fine wrinkles, skin laxity and uneven pigmentation.
The MiXto SX Micro Fractional CO2 Laser is a revolutionary new treatment for skin rejuvenation. It makes it possible for you to have healthy, younger looking skin with minimal post treatment down time. A single treatment can show significant improvement in skin texture and color while softening wrinkles.
Photoprotective Drug Afamelanotide Moves a Step Closer to Market
Melbourne-based Clinuvel Pharmaceuticals Limited (ASX: CUV) achieved positive interim results of its photoprotective drug, afamelanotide, in a Phase III trial conducted in Switzerland. The trial investigated the medical benefits of afamelanotide in the orphan disease erythropoietic protoporphyria (EPP), a severe genetic disorder causing absolute ultraviolet radiation (UV) and light intolerance in the skin. This is the company’s first Phase III test result.
People with EPP, a rare disease, suffer phototoxicity, painful symptoms from sunlight and UV exposure. Phototoxicity usually starts in early childhood with patients experiencing severe burning pain and blistering of the skin, typically on the face and hands. Severe symptoms may last for several days and may be accompanied by swelling and redness on sun exposed areas. EPP is exacerbated in the spring and summer months.
The drug afamelanotide stimulates the body’s own natural melanin production. Melanin is known for its photoprotection as it absorbs ultraviolet radiation, shielding the skin from the effects of UV. This offers EPP patients the possibility of a better quality of life where they don’t have to avoid the sun or live in the shadows.
Fitness Monitoring
This site complies with the HONcode standard for trustworthy health information:
verify here.
About - Terms of use - Privacy Policy
Upgrade Your Body (TM) is managed by Consolidated Computing Pty Ltd.